Clinical Trial Detail

NCT ID NCT04250051
Title Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Northwestern University
Indications

acute myeloid leukemia

Therapies

Cytarabine + Filgrastim + Fludarabine + Ivosidenib

Ivosidenib

Age Groups: senior adult

Additional content available in CKB BOOST